Our study extends this body of work by evaluating a three-marker panel (creatinine, cystatin C and β2M) within the 2021 CKD-EPI equations in a Malaysian CKD cohort, providing novel regional data and supporting the feasibility of a multi-marker strategy in this population. The gene discussed is CST3; the disease is chronic kidney disease.